Key statistics
On Monday, Arbutus Biopharma Corp (0SGC:LSE) closed at 3.76, -19.68% below its 52-week high of 4.68, set on Sep 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 3.76 |
Low | 3.76 |
Bid | -- |
Offer | -- |
Previous close | 3.84 |
Average volume | 10.71k |
---|---|
Shares outstanding | 188.78m |
Free float | 146.68m |
P/E (TTM) | -- |
Market cap | 724.92m USD |
EPS (TTM) | -0.4416 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 18:48 BST.
More ▼
Announcements
- Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
- Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
- Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
- Arbutus to Participate in Jefferies Global Healthcare Conference
- Arbutus to Present Imdusiran Data at EASL Congress 2024
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
More ▼